Comparability of six different immunoassays measuring SARS‐CoV‐2 antibodies with neutralizing antibody levels in convalescent plasma: From utility to prediction

Convalescent plasma (CP) therapy for coronavirus disease (COVID‐19) provides virus‐neutralizing antibodies that may ameliorate the outcome of severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) infections. The effectiveness of CP likely depends on its antiviral neutralizing potency and is determined using in vitro neutralizing antibody assays.

[1]  E. Robilotti,et al.  Association of Convalescent Plasma Therapy With Survival in Patients With Hematologic Cancers and COVID-19 , 2021, JAMA oncology.

[2]  F. Krammer.  Correlates of protection from SARS-CoV-2 infection , 2021, The Lancet.

[3]  William T. Harvey,et al.  Author Correction: Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited antibodies , 2021, Nature.

[4]  M. Landray,et al.  Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial , 2021, medRxiv.

[5]  M. Beer,et al.  SARS-CoV-2 spike D614G change enhances replication and transmission , 2021, Nature.

[6]  Nguyen H. Tran,et al.  Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials , 2021, The Lancet.

[7]  F. Polack,et al.  Prevention of severe COVID-19 in the elderly by early high-titer plasma therapy , 2021, The New England Journal of Medicine.

[8]  John P. Moore,et al.  Convalescent plasma-mediated resolution of COVID-19 in a patient with humoral immunodeficiency , 2020, Cell Reports Medicine.

[9]  Mingshan Xue,et al.  The role of serum specific- SARS-CoV-2 antibody in COVID-19 patients , 2020, International Immunopharmacology.

[10]  M. Drebot,et al.  Evaluation of a commercially-available surrogate virus neutralization test for severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) , 2020, Diagnostic Microbiology and Infectious Disease.

[11]  M. Beer,et al.  SARS-CoV-2 spike D614G variant confers enhanced replication and transmissibility , 2020, bioRxiv.

[12]  P. Klenerman,et al.  A haemagglutination test for rapid detection of antibodies to SARS-CoV-2 , 2020, Nature Communications.

[13]  J. Bloom,et al.  Neutralizing antibodies correlate with protection from SARS-CoV-2 in humans during a fishery vessel outbreak with high attack rate , 2020, medRxiv.

[14]  Rachel J. Johnson,et al.  Convalescent plasma treatment for SARS-CoV-2 infection: analysis of the first 436 donors in England, 22 April to 12 May 2020 , 2020, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[15]  C. Rice,et al.  Convergent Antibody Responses to SARS-CoV-2 in Convalescent Individuals , 2020, Nature.

[16]  P. Simmonds,et al.  Convalescent plasma therapy for the treatment of patients with COVID‐19: Assessment of methods available for antibody detection and their correlation with neutralising antibody levels , 2020, medRxiv.

[17]  Christopher Earl,et al.  Preexisting and de novo humoral immunity to SARS-CoV-2 in humans , 2020, Science.

[18]  Malik Peiris,et al.  Serological assays for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), March 2020 , 2020, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[19]  Gregg Pratt,et al.  DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration , 1998 .